78 related articles for article (PubMed ID: 15904635)
1. Cost effectiveness of rosuvastatin in treating patients to low-density lipoprotein cholesterol goals compared with atorvastatin, pravastatin, and simvastatin (a US Analysis of the STELLAR Trial).
Miller PS; Smith DG; Jones P
Am J Cardiol; 2005 Jun; 95(11):1314-9. PubMed ID: 15904635
[TBL] [Abstract][Full Text] [Related]
2. The power of statins: aggressive lipid lowering.
Stein EA
Clin Cardiol; 2003 Apr; 26(4 Suppl 3):III25-31. PubMed ID: 12708636
[TBL] [Abstract][Full Text] [Related]
3. Statins for atherosclerotic cardiovascular disease prevention in people living with HIV in Thailand: a cost-effectiveness analysis.
Boettiger DC; Newall AT; Chattranukulchai P; Chaiwarith R; Khusuwan S; Avihingsanon A; Phillips A; Bendavid E; Law MG; Kahn JG; Ross J; Bautista-Arredondo S; Kiertiburanakul S
J Int AIDS Soc; 2020 Jun; 23 Suppl 1(Suppl 1):e25494. PubMed ID: 32562359
[TBL] [Abstract][Full Text] [Related]
4. Managing dyslipidemia in primary care with restricted access to lipid-modifying therapy.
Lynch JT; Cooke CE; Rosen J; Gandhi S; Bullano MF
Am Health Drug Benefits; 2010 Sep; 3(5):340-9. PubMed ID: 25126327
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of rosuvastatin in comparison with generic atorvastatin and simvastatin in a Swedish population at high risk of cardiovascular events.
Gandhi SK; Jensen MM; Fox KM; Smolen L; Olsson AG; Paulsson T
Clinicoecon Outcomes Res; 2012; 4():1-11. PubMed ID: 22347800
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of rosuvastatin versus atorvastatin, simvastatin, and pravastatin from a Canadian health system perspective.
Costa-Scharplatz M; Ramanathan K; Frial T; Beamer B; Gandhi S
Clin Ther; 2008 Jul; 30(7):1345-57. PubMed ID: 18691996
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness and cost-effectiveness of rosuvastatin, atorvastatin, and simvastatin among high-risk patients in usual clinical practice.
Ohsfeldt RL; Gandhi SK; Fox KM; Stacy TA; McKenney JM
Am J Manag Care; 2006 Nov; 12(15 Suppl):S412-23. PubMed ID: 17112329
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of rosuvastatin compared with other statins from a managed care perspective.
Benner JS; Smith TW; Klingman D; Tierce JC; Mullins CD; Pethick N; O'Donnell JC
Value Health; 2005; 8(6):618-28. PubMed ID: 16283862
[TBL] [Abstract][Full Text] [Related]
9. Comparison of efficacy, safety, and cost-effectiveness of various statins in dyslipidemic diabetic patients.
Bener A; Dogan M; Barakat L; Al-Hamaq AO
Indian J Pharmacol; 2014; 46(1):88-93. PubMed ID: 24550591
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of rosuvastatin vs generic atorvastatin in Spain.
Barrios V; Lobos JM; Serrano A; Brosa M; Capel M; Alvarez Sanz C
J Med Econ; 2012; 15 Suppl 1():45-54. PubMed ID: 22954062
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of rosuvastatin for primary prevention of cardiovascular events according to Framingham Risk Score in patients with elevated C-reactive protein.
MacDonald GP
J Am Osteopath Assoc; 2010 Aug; 110(8):427-36. PubMed ID: 20805548
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of the use of a high-intensity statin compared to a low-intensity statin in the management of patients with familial hypercholesterolaemia.
Nherera L; Calvert NW; Demott K; Humphries SE; Neil HA; Minhas R; Thorogood M
Curr Med Res Opin; 2010 Mar; 26(3):529-36. PubMed ID: 20014994
[TBL] [Abstract][Full Text] [Related]
13. Early high-dose lipid-lowering therapy to avoid cardiac events: a systematic review and economic evaluation.
Ara R; Pandor A; Stevens J; Rees A; Rafia R
Health Technol Assess; 2009 Jul; 13(34):1-74, 75-118. PubMed ID: 19604457
[TBL] [Abstract][Full Text] [Related]
14. Lipid-lowering efficacy of atorvastatin.
Adams SP; Tsang M; Wright JM
Cochrane Database Syst Rev; 2015 Mar; 2015(3):CD008226. PubMed ID: 25760954
[TBL] [Abstract][Full Text] [Related]
15. Lipid-lowering efficacy of rosuvastatin.
Adams SP; Sekhon SS; Wright JM
Cochrane Database Syst Rev; 2014 Nov; 2014(11):CD010254. PubMed ID: 25415541
[TBL] [Abstract][Full Text] [Related]
16. Cost estimation of cardiovascular disease events in the US.
O'Sullivan AK; Rubin J; Nyambose J; Kuznik A; Cohen DJ; Thompson D
Pharmacoeconomics; 2011 Aug; 29(8):693-704. PubMed ID: 21585226
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of rosuvastatin in the management of dyslipidemia.
Rubba P; Marotta G; Gentile M
Vasc Health Risk Manag; 2009; 5(1):343-52. PubMed ID: 19436657
[TBL] [Abstract][Full Text] [Related]
18. Statin therapy in rheumatoid arthritis: a cost-effectiveness and value-of-information analysis.
Bansback N; Ara R; Ward S; Anis A; Choi HK
Pharmacoeconomics; 2009; 27(1):25-37. PubMed ID: 19178122
[TBL] [Abstract][Full Text] [Related]
19. Atorvastatin and cardiovascular risk in the elderly--patient considerations.
Acharjee S; Welty FK
Clin Interv Aging; 2008; 3(2):299-314. PubMed ID: 18686752
[TBL] [Abstract][Full Text] [Related]
20. Productivity loss as a major component of disease-related costs in patients with hypercholesterolemia in Germany.
Müller-Nordhorn J; Englert H; Wegscheider K; Berger H; Sonntag F; Völler H; Meyer-Sabellek W; Reinhold T; Windler E; Katus HA; Willich SN
Clin Res Cardiol; 2008 Mar; 97(3):152-9. PubMed ID: 18060377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
